Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility

Infection Control and Hospital Epidemiology

Volumn 34, Issue 10, 2013, Pages 1070-1076

  Han, Jennifer H ^a   Bilker, Warren B ^a   Nachamkin, Irving ^b   Tolomeo, Pam ^a   Mao, Xiangqun ^b   Fishman, Neil O ^a   Lautenbach, Ebbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEPHALOSPORIN; LEVOFLOXACIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; COHORT ANALYSIS; DRUG EXPOSURE; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL TRACT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEOPLASM; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; CARRIER STATE; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; FEMALE; FLUOROQUINOLONES; GASTROINTESTINAL TRACT; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84884187285     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/673155     Document Type: Article

References (36)

1. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259-268.
2. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004;38:655-662.
3. Camins BC, Marschall J, DeVader SR, Maker DE, Hoffman MW, Fraser VJ. The clinical impact of fluoroquinolone resistance in patients with E. coli bacteremia. J Hosp Med 2011;6:344-349.
4. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005;41:923-929.
5. Chang TM, Lu PL, Li HH, Chang CY, Chen TC, Chang LL. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J Chemother 2007;19:488-494.
6. Singh R, Swick MC, Ledesma KR, et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012;56:1680-1685.
7. Kern WV, Oethinger M, Jellen-Ritter AS, Levy SB. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2000;44: 814-820.
8. Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis 2006;43(suppl 2):S62-S69.
9. Richard P, Delangle MH, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001;32:162-166.
10. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162: 2469-2477.
11. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008;121:876-884.
12. van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011;66:650-656.
13. Huotari K, Tarkka E, Valtonen V, Kolho E. Incidence and risk factors for nosocomial infections caused by fluoroquinoloneresistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003;22: 492-495.
14. Lin CY, Huang SH, Chen TC, Lu PL, Lin WR, Chen YH. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates. J Microbiol Immunol Infect 2008;41:325-331.
15. Arslan H, Azap OK, Ergonul O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005;56:914-918.
16. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568-574.
17. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinoloneresistant E. coli. Infection 2008;36:41-45.
18. McDonald LC, Chen FJ, Lo HJ, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001;45:3084-3091.
19. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004;38:1148-1152.
20. Lautenbach E, Metlay JP, Weiner MG, et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009;30:18-24.
21. de Lastours V, Chau F, Tubach F, Pasquet B, Ruppe E, Fantin B. Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission. Antimicrob Agents Chemother 2010;54:5193-5200.
22. Hota BN, Pur S, Phillips L, Weinstein RA, Segreti J. Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2005;24:405-410.
23. Yagci D, Yoruk F, Azap A, Memikoglu O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009;53:1287-1289.
24. Perea S, Hidalgo M, Arcediano A, et al. Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother 1999;44: 117-120.
25. Lautenbach E, Fishman NO, Metlay JP, et al. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006;194:79-85.
26. Gales AC, Gordon KA, Wilke WW, Pfaller MA, Jones RN. Occurrence of single-point gyrA mutations among ciprofloxacinsusceptible Escherichia coli isolates causing urinary tract infections in Latin America. Diagn Microbiol Infect Dis 2000;36:61-64.
27. Lee I, Fishman NO, Zaoutis TE, et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009;169:379-383.
28. Barton TD, Fishman NO, Weiner MG, LaRosa LA, Lautenbach E. High rate of coadministration of di-or tri-valent cationcontaining compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005; 26:93-99.
29. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-137.
30. Han JH, Nachamkin I, Tolomeo P, Mao X, Bilker WB, Lautenbach E. Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones. Diagn Microbiol Infect Dis 2013;76:491-496.
31. Hyle EP, Bilker WB, Gasink LB, Lautenbach E. Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibioticresistant infection. Infect Control Hosp Epidemiol 2007;28:647-654.
32. Keeney D, Ruzin A, McAleese F, Murphy E, Bradford PA. MarAmediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008;61:46-53.
33. Swick MC, Morgan-Linnell SK, Carlson KM, Zechiedrich L. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob Agents Chemother 2011;55:921-924.
34. Sahm DF, Critchley IA, Kelly LJ, et al. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2001;45:267-274.
35. Han JH, Nachamkin I, Tolomeo P, Mao X, Bilker WB, Lautenbach E. Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli. J Infect Dis 2012;206: 1597-1603.
36. Bolon MK, Wright SB, Gold HS, Carmeli Y. The magnitude of the association between fluoroquinolone use and quinoloneresistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother 2004; 48:1934-1940.